Latanoprost 130209-82-4
145773-22-4
Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension by reducing intraocular pressure. It is a prostaglandin analogue (more specifically an analogue of Prostaglandin F2α) that works by increasing the outflow of aqueous fluid from the eyes (through the uvealsclearal tract). It is also known by the brand name of Xalatan manufactured by Pfizer. Annual sales are approximately $1. 6 billion. The patent for latanoprost expires in 2011. Latanoprost was developed by Dr. Carl B. Camras and his research adviser Dr. László Z. Bitó at Columbia University in 1996.
Adverse reactions
Possible side effects:
- May cause reddening of the eyes
- May cause blurred vision;
- May cause eyelid redness;
- May permanently darken eyelashes;
- May cause eye discomfort;
- May eventually cause permanent darkening of the iris to brown ;
- May cause a temporary burning sensation during use.
- May cause thickening of the eyelashes.
- Rarely, herpes simplex keratitis.
- A single case report links latanoprost use to the progression of keratoconus.
| Systematic (IUPAC) name: | isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl] hept-5-enoate |
|---|---|
| Latanoprost CAS number: | 130209-82-4 145773-22-4 |
| ATC code: | S01EE01 |
| PubChem: | 5311221 |
| DrugBank: | APRD01065 |
| Formula: | C26H40O5 |
| Molecular mass: | 432.593 g/mol |
| Latanoprost Assay/Purity: | Typically NLT 98% |
